Substance / Medication

Octreotide acetate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Acromegaly

Neoplasm of pancreas

Neoplasm of pituitary gland

Benign adenomatous neoplasm

Adenoma

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

15 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex

NCT00001452Completed1387 enrolled

Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly

NCT00376064Phase 4Completed20 enrolled

Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly

NCT00461149Phase 4Completed50 enrolled

Endoscopy Nurse Participation in Adenoma Detection Rate During Colonoscopy

NCT01124266Phase 4Completed844 enrolled

Surgical Debulking of Pituitary Adenomas

NCT01371643Phase 4Completed41 enrolled

View all 15 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Relative Bioavailability of a Single 4-mg Dose of Somatropin Administered by Subcutaneous Injection or by Needle-free Device and Coadministered With the Growth Hormone Inhibitor Octreotide Acetate in Healthy Adult Subjects.

Brimhall Darin B, Petri Niclas, D'Angelo Pina · Clin Ther · 2018

PMID: 29699852RCT

Octreotide acetate in prevention of chemoradiation-induced diarrhea in anorectal cancer: randomized RTOG trial 0315.

Zachariah Babu, Gwede Clement K, James Jennifer et al. · J Natl Cancer Inst · 2010

PMID: 20339140RCTFull text (PMC)

Role of 99mTc-octreotide acetate scintigraphy in suspected lung cancer compared with 18F-FDG dual-head coincidence imaging.

Wang Feng, Wang Zizheng, Yao Weixuan et al. · J Nucl Med · 2007

PMID: 17704242Observational

Octreotide scintigraphy and Chromogranin A do not predict clinical response in patients with octreotide acetate-treated hormone-refractory prostate cancer.

Kalkner K M, Acosta S, Thorsson O et al. · Prostate Cancer Prostatic Dis · 2006

PMID: 16231013Observational

In vivo release kinetics of octreotide acetate from experimental polymeric microsphere formulations using oil/water and oil/oil processes.

Murty Santos B, Wei Qui, Thanoo B C et al. · AAPS PharmSciTech · 2004

PMID: 15760082ObservationalFull text (PMC)

Ciliary body toxicity of cyclosporin A and octreotide acetate in rabbit eyes: a comparison with mitomycin C and 5-fluorouracil.

Akyol Nuray, Demir Tamer, Cobanoglu Bengu et al. · Graefes Arch Clin Exp Ophthalmol · 2003

PMID: 13680250Observational

[The Use of Octreotide Acetate in the Management of Refractory Chylothorax Following Surgical Treatment for Lung Cancer].

Kawakami Toru, Ishida Itaru, Sugawara Takafumi et al. · Kyobu Geka · 2016

PMID: 27246125Case Report

[Successful treatment of a case of chylothorax, manifesting as a complication following surgical treatment of coarctation of the aorta, by using octreotide acetate; report of a case].

Matsushita Hiroshi, Hanayama Naoji · Kyobu Geka · 2014

PMID: 24743487Case Report

Octreotide acetate administration for malignant bowel obstruction induces severe bradycardia in patients with terminal stage cancer: two case reports.

Kubota Kazuko, Hasumi Yoko, Numata Aya et al. · J Palliat Med · 2013

PMID: 23600413Case Report

[Postoperative refractory chylothorax which was improved by octreotide acetate].

Gabe Atsushi, Seki Masahiro, Taira Naohiro et al. · Kyobu Geka · 2012

PMID: 22374601Case Report

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Octreotide acetate (substance)
SNOMED CT: 109055007
UMLS CUI: C0724649

Clinical Data

This intervention maps to 5 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.